Anti-Human FGF-19

E. coli-Derived Recombinant Human FGF-19

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Blocking: Approximately 2-8 μg/ml of this antibody will block 50% of the binding of 200 ng/ml of rhFGF-19 to immobilized rhFGF R4/Fc chimera (100 μL of a 2 μg/ml solution was coated in each well) in a functional ELISA.

Goat Anti-Human Fibroblast Growth Factor 19 (FGF-19) recognizes Human FGF-19. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

Fibroblast growth factor 19, also known as FGF19 is an atypical member of the fibroblast growth factor (FGF) family of proteins. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes including embryonic development cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF19 uniquely binds to FGF receptor 4 (FGFR4).¹

The FGF19 subfamily has reduced heparin binding resulting from a disrupted beta-trefoil domain. Reduced heparin binding allows these FGFs to diffuse beyond their site of origin and act as endocrine hormones. This family of FGFs is regulated, at least in part, by nuclear hormone receptors.² Inactivation of FGF19 could be beneficial for the treatment of colon cancer, liver cancer and other malignancies involving interaction of FGF19 and FGFR4.³

1. French, DM. et al. (2008) Cancel Res. 68: 5086
2. Jones, S. et al. (2008) Mol Pharm. 5: 42
3. French, DM. et al. (2008) Oncogene 27: 85